R&D strategy

R&D strategy Agency Consulting firm Experts Specialists Consultancy

Develop your pipeline strategy and R&D portfolio management

For more than 30 years, our specialized team has been supporting companies in developing successful research and development strategies (with the ability to fuel, create and maintain a strong pipeline of innovative products or services) and to adopt effective R&D portfolio management, while aligning organizations cross-functionally.

    Tell us about your uncharted territory

    You have a project and want to discuss it with our explorers, write us!

    One of our explorers will contact you shortly.

    They trust us


    The challenges related to R&D strategy

    As R&D strategies are crucial for businesses’ growth, they should be developed with input from across all the key company stakeholders. Any new product is always in relation to ever-changing technical and market dynamics, so companies need to keep a finger on the pulse of each sector they play in (or will play in) and be able to anticipate the key trends to correctly time the decision to push development forward or stop.

    The key challenges in R&D strategy are:

      Tell us about your uncharted territory

      You have a project and want to discuss it with our explorers, write us!

      One of our explorers will contact you shortly.

      How we support you in your R&D srategy and R&D portfolio management

      At Alcimed, we help our clients in their pipeline and portfolio strategies at all stages of their research and development stages:

      • Across the scientific and industrial research ecosystem: R&D departments of innovative industry leaders, academic labs and KOLs, spin-off start-ups, biotechs/medtechs
      • Of various sizes: major pharmaceutical, biotech and medtech manufacturers, as well as smaller innovative companies
      • With functions across R&D: pipeline & portfolio strategies, New Product Strategy, Translational research, External Innovation, etc.
      • At all stages of R&D: In pre-discovery, discovery, preclinical and clinical development stages up to a new product launch
      • On their in-line assets and new products pipeline (drugs, medtech) and R&D supporting technologies and models (e.g. biomarkers, assays, high-throughput screening, in silico modeling, etc.)

      We leverage Alcimed’s 30-year presence in the field and our team of scientific and medical background and training to continuously observe, explore, interact with key research stakeholders in the healthcare innovation space and analyze the trends in the scientific field and industrial applications, to guide our clients in the organization and advancement of their R&D pipeline.

      Key topics we have covered include: scientific state-of-the-art to identify new research areas (metabolic pathways, mechanism of actions, etc.) and identify trending drug modalities and new drug discovery platform to create; identifying and evaluating new assays and biomarker candidates to develop and include to clinical development programs; assessing the competitive landscape in the research and clinical development space; early opportunity evaluation and go/no go assessment for platform or program development; organization of the go/no-go decision-making process at every steps of the research and development program… among many other topics!

      What they say

      • TCV_Nestle_HS_miniature_site_EN_min

        Bernard Cuenoud

        Global Head of Research and Clinical Development

      • TCV_Innovio_miniature_site_EN_min

        Mark TWYMAN

        Senior VP and Chief Commercial Officer

      • TCV_biomerieux_miniature_site_EN_min

        Lionel LIMOUSY


      Examples of recent R&D strategies carried out for our clients

      • Assessing the translatability of a novel technology platform

        A client wanted to understand what the potential lead indications would be best suited to prove the therapeutic value of its immune regulatory platform.

        Alcimed conducted an analysis of the state-of-the-science, helped prioritize potential therapeutic cellular targets to place into R&D to regulate complement fixation both when it creates or prevents disease, and recommended potential academic and private research labs to collaborate with as part of the client’s R&D strategy and capability requirements roadmap.

      • Diagnosis & vision for a new pipeline assessment process

        An innovative biotech companies asked for our help to strengthen its pipeline evaluation process, to be more robust, systematic and reproductible across its current and future drug development programs, as well as more specific to its strategic vision, culture, and organization.

        After aligning the executive team around a common vision of the process need, Alcimed brought inspirational benchmarks and led the collaborative building of a new process of stage-gated evaluation and decision-making of its existing and future pipeline.

      • Building a business case with early opportunity evaluation for new diseases

        The R&D portfolio strategy team of a pharmaceutical company needed help to lead its choice of the next diseases to invest research & development for, based on a first high-level landscaping of five markets of interest (high medical unmet need).

        Alcimed reconstructed such landscapes by analyzing critical industry parameters (epidemiology, unmet need, competition now and in development, etc.) and in the end gave a go/no-go, prioritization and “how to” recommendation.

      • Strategy to improve the R&D performance of an industrial player

        We helped a leading company in the space industry improve its R&D strategy. Our client’s main challenge was to build a reference framework that would enable it to assess the relevance of the projects in its R&D portfolio. It would allow our client to objectively decide which project to pursue or discontinue, and ultimately optimize performance.

        We carried out an initial internal phase aimed at understanding the existing R&D process, its pain points and the key criteria to be considered in order to optimize project analysis. We then benchmarked with comparable players (very long product cycles, substantial R&D investment, ….) to understand best practices and pitfalls to avoid in this area.

        All the elements gathered enabled us to build a customized reference framework (criteria, an evaluation scale for each criterion, metrics, etc.) integrating the dimensions of strategic fit, business elements, degree of innovation, human aspects, etc.

      • Development of the AI ambition of a public institution in terms of R&D, as well as its strategic roadmap and the identification of relevant partners

        Our client, a public institution in the healthcare sector, wanted to define its ambition in terms of AI for its R&D activities, as well as the best means of implementing it.

        Capitalising on an initial mapping exercise, we defined the internal needs of the various R&D teams and the potential applications of AI in their activities. We then investigated a wide range of existing technological solutions, to identify those that could meet the needs identified and that were accessible in terms of cost and ease of implementation. The most relevant potential partners for their implementation were also identified and prioritised.

        Finally, Alcimed supported this public institution in the construction of a clear roadmap for the implementation of the priority solutions.

      • Identification of trends impacting on Research & Development & Innovation (R&D&I) in the materials sector to help structure the scientific roadmap of a research institute

        Our team helped a research institute in the materials sector to structure its scientific roadmap by understanding the technological, economic, societal and regulatory trends impacting R&D&I in this sector.

        Alcimed carried out a strategic foresight study to define the main cross-cutting trends impacting materials research in the future and identified the 40 trends impacting R&D&I in the sector. These trends were prioritised on the basis of their cross-disciplinary nature and impact. This strategic study provided input for the Institute’s scientific roadmap.

        Finally, Alcimed also consolidated a collection of best practices for the renewal of a label promoting access to funding.

      You have a project?

        Tell us about your uncharted territory

        You have a project and want to discuss it with our explorers, write us!

        One of our explorers will contact you shortly.